Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study

BACKGROUND: Up to 6-months oxaliplatin-containing regimen is now widely accepted as a standard adjuvant chemotherapy for stage III colorectal cancer (CRC). However, oral fluoropyrimidine monotherapy is used for some part of patients, especially in Asian countries including Japan, and its optimal dur...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Br J Cancer
Main Authors: Tomita, Naohiro, Kunieda, Katsuyuki, Maeda, Atsuyuki, Hamada, Chikuma, Yamanaka, Takeharu, Sato, Toshihiko, Yoshida, Kazuhiro, Boku, Narikazu, Nezu, Riichiro, Yamaguchi, Shigeki, Mishima, Hideyuki, Sadahiro, Sotaro, Muro, Kei, Ishiguro, Megumi, Sakamoto, Junichi, Saji, Shigetoyo, Maehara, Yoshihiko
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group UK 2019
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6461756/
https://ncbi.nlm.nih.gov/pubmed/30833647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0410-0
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים